Psychedelic-assisted therapies offer hope for conditions like treatment-resistant depression, PTSD, substance use disorders, and generalized anxiety disorder. Yet, many Americans, including veterans, travel abroad for these therapies due to limited availability in the U.S.
The federal government should act to ensure these therapies are accessible. While the Trump administration accelerated research, more is needed to bring these therapies safely to those in need.
130 Americans die by suicide each day, including over 20 veterans daily.
The bipartisan Congressional Psychedelics Advancing Therapies (PATH) Caucus seeks to integrate psychedelic medicine into U.S. healthcare. Feedback indicates psychedelics can be transformative if used safely.
A national framework is essential for safe and equitable access. Feedback suggests accelerating medical development while ensuring safety, ethics, and equity. National standards for service delivery and practitioner credentials are crucial before FDA approval.
Labeling requirements and best practices for therapy administration are necessary. Treatment should encompass crisis response, pre- and post-session support.
The entrance of psychedelic-assisted therapies into American healthcare is a question of when, not if. Focus must be on their safe and effective integration, granting access to those in need.
Congress must act to establish standards that protect patients and ensure equitable access, improving mental and physical health for Americans.
Jack Bergman represents Michigan’s 1st Congressional District and Lou Correa represents California’s 46th District. Both serve as Congressional PATH Caucus co-chairs.
Youth Protests Challenge Modi’s Political Authority 
Today’s Political Headlines 
Katie Zacharia Takes the Helm as White House Press Secretary 
Key Supreme Court Cases to Watch 
Addressing Congressional Spending Addiction 
Trump Administration Requests Ambassador Kimberly Guilfoyle’s Resignation